Nitrosamine impurity controls in pharma APIs: current regulatory expectations

What are the current regulatory expectations for nitrosamine impurity controls in pharmaceutical APIs?

Regulatory agencies worldwide have converged on a risk‑based framework for nitrosamine control. The International Council for Harmonisation (ICH) M7 guideline defines acceptable daily intake (ADI) limits for each nitrosamine, typically ranging from 0.018 µg day⁻¹ (N‑nitrosodiethylamine) to 0.96 µg day⁻¹ (NDMA)【1】. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have translated these ADIs into concentration limits for APIs, most commonly 0.5 ppm (0.5 µg g⁻¹) for NDMA and equivalent limits for other nitrosamines【2】【3】. Companies must demonstrate that their manufacturing processes either avoid nitrosamine formation or keep levels below these thresholds through validated analytical testing and appropriate mitigation.

How should manufacturers conduct a nitrosamine risk assessment for an API?

A compliant risk assessment follows a four‑step approach:

1. Identify potential nitrosamine sources – reagents (e.g., secondary amines, nitrosating agents), solvents (e.g., dimethylformamide), and equipment (e.g., stainless‑steel surfaces) that can generate nitrosamines under acidic conditions.
2. Evaluate reaction pathways – use mechanistic knowledge and literature data to predict nitrosation likelihood. The EMA’s 2020 guideline provides a decision tree for this purpose【3】.
3. Quantify exposure – calculate the worst‑case nitrosamine concentration based on stoichiometry, impurity levels of starting materials, and process yields. Compare the result with the ADI‑derived limit.
4. Implement controls – if the predicted level exceeds the limit, modify the process (e.g., replace nitrite‑containing reagents, adjust pH, introduce scavengers) or introduce additional purification steps.

Documentation must be retained in the drug substance dossier, including a summary of the risk assessment, justification for chosen limits, and any mitigation measures.

Which analytical methods are accepted for detecting nitrosamines in APIs?

Regulators expect methods that meet the following criteria:

• Sensitivity: limit of detection (LOD) ≤ 0.1 µg kg⁻¹ for NDMA and comparable values for other nitrosamines.
• Selectivity: ability to resolve nitrosamines from matrix interferences.
• Validation: compliance with ICH Q2(R1) for parameters such as accuracy (recovery 80‑120 %), precision (RSD ≤ 15 %), linearity (R² ≥ 0.99), and robustness.

The most widely accepted techniques are:

• Gas chromatography‑mass spectrometry (GC‑MS) with selected ion monitoring (SIM) – provides LODs down to 0.02 µg kg⁻¹ for NDMA【4】.
• Liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) – increasingly used for polar nitrosamines where GC is less suitable.
• Headspace GC‑MS – useful for volatile nitrosamines in solvents.

Method transfer between laboratories should be supported by a reference standard traceable to a certified reference material (CRM) such as those supplied by the National Institute of Standards and Technology (NIST) or the European Pharmacopoeia (EP).

What are the reporting and post‑approval obligations for nitrosamine impurities?

Both the FDA and EMA require:

• Initial submission: inclusion of nitrosamine limits and analytical data in the IND/CTA and the marketing authorisation dossier.
• Periodic safety update reports (PSURs): any change in nitrosamine levels, new findings, or process modifications must be reported within 30 days of discovery.
• Change control: any alteration to raw material suppliers, synthetic routes, or equipment that could affect nitrosamine formation triggers a supplemental NDA/MAA filing.
• Recall readiness: manufacturers must have a product recall plan that includes testing of retained batches for nitrosamines if a breach is suspected.

Non‑compliance can lead to warning letters, product holds, or market withdrawals, as illustrated by the 2020 NDMA recalls affecting valsartan and ranitidine products【5】.

How can Molekula support compliance with nitrosamine regulations?

Molekula provides high‑purity reagents with full certificates of analysis (CoA) that include nitrosamine testing where relevant. Their catalogue includes nitrite‑free amine sources and validated solvent grades that meet USP/EP specifications, helping customers reduce the intrinsic risk of nitrosamine formation during synthesis.

Sources

Frequently asked

Q1: What is the typical ADI for NDMA? A: The FDA sets an ADI of 0.096 µg day⁻¹ for NDMA, which translates to a concentration limit of 0.5 ppm in most APIs.

Q2: Are there any nitrosamines exempt from the 0.5 ppm limit? A: No; all nitrosamines listed in ICH M7 are subject to the same risk‑based limits unless a specific ADI dictates a lower value.

Q3: Can a single analytical method cover all nitrosamines? A: GC‑MS with SIM can detect most volatile nitrosamines, but polar nitrosamines often require LC‑MS/MS for adequate sensitivity.

Q4: How often should nitrosamine testing be performed? A: At a minimum, testing is required for each batch release and whenever a process change could affect nitrosamine formation.